13 results about "Endotoxemias" patented technology

The invention discloses an application of squalene or a pharmaceutically acceptable salt thereof in preparation of a medicine for preventing or treating endotoxemia. Experiments show that squalene significantly relieves LPS-induced endotoxemia liver injury through a multi-target mechanism, squalene not only relieves inflammatory response by inhibiting release of inflammatory factors, but also relieves oxidative stress by activating an antioxidant pathway, and the squalene has dual action mechanisms. The invention further provides application of the squalene-containing composition to preparation of the medicine for treating endotoxemia, squalene and glucocorticoid show a synergistic effect in the aspect of inhibiting TNF-alpha, AST can be reduced more remarkably by combining squalene and glucocorticoid, and the effect of dual inhibition of inflammatory mediators is achieved. Besides, the composition of the inducible nitric oxide synthase and squalene is applied to the preparation of the medicine for treating endotoxemia, and the inducible nitric oxide synthase inhibitor can inhibit the activity of iNOS, so that the excessive generation of nitric oxide is reduced, and the inflammatory reaction is further inhibited synergistically.

The invention relates to the technical field of animal model construction, and particularly discloses a construction method of an atherosclerotic plaque thrombosis model. Comprising the following steps: 1) selecting carotid artery constricted ApoE- / -mice fed with high-fat feed; and 2) injecting LPS (Lipopolysaccharide) into the abdominal cavity to obtain the atherosclerotic plaque thrombosis animal model. The construction method provided by the invention is simple to operate and high in repeatability, atherosclerotic plaque thrombus formation can be induced under the stimulation of low-dose LPS, the thrombus occurrence rate equivalent to the thrombus occurrence rate in the prior art can be obtained, the construction method can be closer to the formation of atherosclerotic thrombus related to clinical endotoxemia, and the clinical pathological process can be better simulated.

The invention relates to a pharmaceutical composition consisting of a liposomal formulation of a phospholipid component and an aqueous phase, wherein the phospholipid component is selected from the group consisting of phosphatidylcholine, and sphingomyelin, and wherein the phospholipid component comprises a saturated or mono-unsaturated (Z / cis) fatty acid having 14 to 20 carbon atoms. The invention further relates to the use of the pharmaceutical composition in treatment of a condition associated with presence of lipopolysaccharide (LPS), particularly endotoxemia.

The invention belongs to the technical field of medicines, and discloses application of cystamine in preparation of a medicine for treating sepsis encephalopathy. Wherein the sepsis encephalopathy is sepsis encephalopathy simulated by an endotoxemia model or an in-vitro reactive astrocyte model. It is found for the first time that cystamine can inhibit the pathological process of sepsis encephalopathy through multiple ways, and the death rate and cognitive impairment of sepsis model mice are remarkably improved. The invention provides a new thought for preparing a sepsis encephalopathy treatment product, and has a wide application prospect.

Probiotic compositions comprising Bacillus subtilis, Bacillus licheniformis and Pediococcus acidilactici in amounts effective for promoting digestive health, decreasing endotoxemia, decreasing diarrhea, decreasing vomiting and increasing the digestibility of foodstuffs in dogs.

The present application relates to the technical field of animal model construction, and specifically discloses a method for constructing an atherosclerotic plaque thrombosis model. ‑ / ‑ The method comprises the following steps: 1) selecting an ApoE The method provided by the present application is simple in operation, high in repeatability, and can induce atherosclerotic plaque thrombosis under the stimulation of a low-dose LPS, and can obtain a thrombosis rate comparable to that of the prior art, and can be closer to the formation of atherosclerotic thrombosis related to clinical endotoxemia, and better simulate the clinical pathological process.

The invention belongs to the field of treatment of inflammatory diseases, and provides application of an EED inhibitor in preparation of a medicine for preventing and treating blood-brain barrier permeability injury caused by endotoxemia. Experiments show that the EED inhibitor significantly reduces blood brain barrier permeability, inhibits neuroinflammation and improves disease behaviors. The invention provides a new medicine and a new way for treating secondary diseases related to endotoxemia.

There is provided a liposomal suspension comprising transmembrane pH-gradient liposomes in an aqueous solution, the suspension comprising citric acid anhydrous and lipids in a ratio of (3.54 g / L) / (6.49 g / L) along with a kit for preparing the liposomal suspension, uses of the liposomal suspension and kits for treating an ammonia- or ammonia methylated analog-associated disease or disorder, or a symptom thereof; endotoxemia; or endotoxemia-associated disease or disorder or a symptom thereof, in a subject in need thereof. Also provided are a system and method for intraperitoneally administering the liposomal suspension to a subject in need thereof.

The invention relates to application of a curcumin analogue C1 in preparation of a medicine for treating endotoxemia, and relates to the technical field of biological medicines. According to the application, after an endotoxin-induced mouse model is intervened by adopting the curcumin analogue C1, TNF-alpha, IL-6, MCP-1, BUN and BNP in serum are all found to be remarkably reduced, and the pathological injury condition of lung tissues and the survival rate / clinical state of mice are all remarkably improved, the pharmacological value of the curcumin analogue C1 in endotoxemia is disclosed, and the curcumin analogue C1 can be used for treating endotoxemia. And a new thought is provided for treatment of inflammatory diseases.

The invention discloses an application of a water-soluble fullerene nano material in preparation of a medicine for treating and / or relieving endotoxemia. The method for treating and / or relieving the endotoxemia comprises the following steps: 1) inhibiting inflammation caused by the endotoxemia; 2) the intestinal epithelial barrier is protected or intestinal epithelial barrier injury caused by endotoxemia is relieved; the inventor of the invention discovers that the water-soluble fullerene blocks the pyroptosis of macrophages induced by inflammation by down-regulating the expression of gasdermin D (N-GSDMD) after cutting for the first time. The AFRM repairs epithelium connection and extracellular matrix, and reduces oxidative damage to intestinal epithelial barrier. The AFRM with broad-spectrum and self-cascade redox regulation characteristics can be used for remodeling the intestinal microenvironment in three aspects of relieving excessive inflammation, inhibiting pyroptosis of macrophages and maintaining the integrity of the intestinal epithelial barrier, so that multi-target synergistic efficient treatment on the LPS-induced endotoxemia is realized.

The present invention belongs to the field of medical technology and discloses the use of cystamine in the preparation of a drug for treating septic encephalopathy. The septic encephalopathy is simulated in an endotoxemia model or an in vitro reactive astrocyte model. The present invention is the first to discover that cystamine can inhibit the pathological progression of septic encephalopathy through multiple pathways, significantly improving mortality and cognitive dysfunction in mice modeled with septic encephalopathy. This invention provides new insights into the preparation of therapeutic products for septic encephalopathy and has broad application prospects.

The present invention relates to the use of an improved curcuminoids composition for reducing LPS levels in blood, reducing endotoxemia, protecting the integrity of the intestinal barrier, treating, decreasing and / or preventing leaky gut syndrome, reducing intestinal lipids absorption, reducing ApoB48 levels in blood and / or for in treating, decreasing and / or preventing dyslipidemia in a subject.